{ "instance": { "rzlt-20220630x10k.htm": { "axisCustom": 0, "axisStandard": 25, "contextCount": 255, "dts": { "calculationLink": { "local": [ "rzlt-20220630_cal.xml" ] }, "definitionLink": { "local": [ "rzlt-20220630_def.xml" ] }, "inline": { "local": [ "rzlt-20220630x10k.htm" ] }, "labelLink": { "local": [ "rzlt-20220630_lab.xml" ] }, "presentationLink": { "local": [ "rzlt-20220630_pre.xml" ] }, "schema": { "local": [ "rzlt-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 568, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 20, "http://www.rezolutebio.com/20220630": 3, "http://xbrl.sec.gov/dei/2022": 5, "total": 28 }, "keyCustom": 119, "keyStandard": 249, "memberCustom": 44, "memberStandard": 26, "nsprefix": "rzlt", "nsuri": "http://www.rezolutebio.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document And Entity Information", "role": "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - LICENSE AGREEMENTS", "role": "http://www.rezolutebio.com/role/DisclosureLicenseAgreements", "shortName": "LICENSE AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - LOAN AND SECURITY AGREEMENT", "role": "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreement", "shortName": "LOAN AND SECURITY AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficiencies", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - SHAREHOLDERS' EQUITY", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity", "shortName": "SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - INCOME TAXES", "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION", "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformation", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - NET LOSS PER SHARE", "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShare", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Consolidated Balance Sheets", "role": "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.rezolutebio.com/role/DisclosureSubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - LEASES (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_DerivativeInstrumentRiskAxis_rzlt_ClassBPreFundedWarrantsMember_71QzNHn64kGkd71v5bGIBg", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:ScheduleOfEquityShareDeficiencyValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_DerivativeInstrumentRiskAxis_rzlt_ClassBPreFundedWarrantsMember_71QzNHn64kGkd71v5bGIBg", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:ScheduleOfEquityShareDeficiencyValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationTables", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - NET LOSS PER SHARE (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)", "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "INF", "first": true, "lang": null, "name": "rzlt:NumberOfWhollyOwnedSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_subsidiary_FLDZVRB29UGDo754-tgTOQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "INF", "first": true, "lang": null, "name": "rzlt:NumberOfWhollyOwnedSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_subsidiary_FLDZVRB29UGDo754-tgTOQ", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - LIQUIDITY (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "shortName": "LIQUIDITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_5_4_2022_To_5_4_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2022Member_h_obtA7-K0i33vHEmRb07w", "decimals": "-5", "lang": null, "name": "rzlt:RemainderOfUnrestrictedEquitySecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - LEASES - Office Space (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails", "shortName": "LEASES - Office Space (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_11_1_2020_To_11_30_2020_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_AncillaryOfficeSpaceMember_aP6vTEN1m06k1epl9WGTmw", "decimals": "0", "lang": null, "name": "rzlt:OperatingLeaseSpace", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_1CT7Z8ZHB0uX2Z9E5KmKVA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - LEASES - Assets and operating lease liabilities (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "shortName": "LEASES - Assets and operating lease liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_AncillaryOfficeSpaceMember_ovVhBXdIRUiHeP2TW_jfog", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_AncillaryOfficeSpaceMember_J3QYiMqKHEGR2KwYqxJpMA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - LEASES - Operating lease expense (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "shortName": "LEASES - Operating lease expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_AncillaryOfficeSpaceMember_J3QYiMqKHEGR2KwYqxJpMA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_AncillaryOfficeSpaceMember_ovVhBXdIRUiHeP2TW_jfog", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - LEASES - Future Operating Lease Payments (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "shortName": "LEASES - Future Operating Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_AncillaryOfficeSpaceMember_ovVhBXdIRUiHeP2TW_jfog", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - LEASES - Headquarters Lease (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "shortName": "LEASES - Headquarters Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_4_1_2022_To_4_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_CorporateHeadquartersMember_g-r9m3fCdE2EiFKUSDhjCw", "decimals": "INF", "lang": null, "name": "rzlt:LesseeOperatingLeaseLeaseNotYetCommencedOperatingLeaseSpace", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_1CT7Z8ZHB0uX2Z9E5KmKVA", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_CorporateHeadquartersMember_LgyYshGISEKRCBTge-I6bg", "decimals": "-3", "first": true, "lang": null, "name": "rzlt:LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40306 - Disclosure - LEASES - Future Payments of Lease Yet to Commence (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "shortName": "LEASES - Future Payments of Lease Yet to Commence (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_rzlt_CorporateHeadquartersMember_LgyYshGISEKRCBTge-I6bg", "decimals": "-3", "first": true, "lang": null, "name": "rzlt:LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "rzlt:LicenseAgreementsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_rzlt_XomaUsLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_rzlt_XomaLicenseAgreementMember_F_CVtXreoE-DVaFFmn-ktw", "decimals": "-5", "first": true, "lang": null, "name": "rzlt:MilestoneClosingPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - LICENSE AGREEMENTS (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "shortName": "LICENSE AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rzlt:LicenseAgreementsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_rzlt_XomaUsLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_rzlt_XomaLicenseAgreementMember_F_CVtXreoE-DVaFFmn-ktw", "decimals": "-5", "first": true, "lang": null, "name": "rzlt:MilestoneClosingPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - LOAN AND SECURITY AGREEMENT (Details)", "role": "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails", "shortName": "LOAN AND SECURITY AGREEMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_4_14_2021_us-gaap_TypeOfArrangementAxis_rzlt_LoanAndSecurityAgreementMember_r1C430n020igrYY9ChwuJQ", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Consolidated Statements of Operations", "role": "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Deficiency Triggered by Issuance of Class B Pre-Funded Warrants (Details)", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Deficiency Triggered by Issuance of Class B Pre-Funded Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_16_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ClassBPreFundedWarrantsMember_KPJSXz04ck-uhwvCsSVt1w", "decimals": "-5", "lang": null, "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Weighted-Average Assumption for Valuations of Class B Pre-Funded Warrants (Details)", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Weighted-Average Assumption for Valuations of Class B Pre-Funded Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_16_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ClassBPreFundedWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KB9KzsEXBkiiZ0pEx-H8JA", "decimals": "2", "lang": null, "name": "rzlt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMarketPriceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2021_1d3ahVSAdk-4BeZR1getXg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Deficiency Triggered by Charter Revision (Details)", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Deficiency Triggered by Charter Revision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rzlt:DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_2_17_2021_yeCW5i7qsUe5fynNsdsGsw", "decimals": "-5", "lang": null, "name": "rzlt:CommonStockRequiredSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "rzlt:ScheduleOfEquityShareDeficiencyTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_5_26_2021_fgFGM1c77kCGnpqeQ5HOxQ", "decimals": "-3", "first": true, "lang": null, "name": "rzlt:CommonStockDeficiencyOfRequiredSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40604 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Derivative Liability Associated with Stock Options (Details)", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Derivative Liability Associated with Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "rzlt:ScheduleOfEquityShareDeficiencyTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_5_26_2021_To_5_26_2021_VfhFndEGCkWQeL8eSzV4XA", "decimals": "2", "lang": null, "name": "rzlt:CommonStockDeficiencyWeightedAverageFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40605 - Disclosure - DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Weighted-Average Assumption for Valuations by Charter Revision (Details)", "role": "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "shortName": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES - Weighted-Average Assumption for Valuations by Charter Revision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_5_26_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_Pf0ou2h9f066Q4hvtj8ZGA", "decimals": "2", "lang": null, "name": "rzlt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMarketPriceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - SHAREHOLDERS' EQUITY - Changes in Authorized Capital Stock (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityChangesInAuthorizedCapitalStockDetails", "shortName": "SHAREHOLDERS' EQUITY - Changes in Authorized Capital Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_2_17_2021_yeCW5i7qsUe5fynNsdsGsw", "decimals": "-5", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - SHAREHOLDERS' EQUITY - May 2022 Registered Direct Offering (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "shortName": "SHAREHOLDERS' EQUITY - May 2022 Registered Direct Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_5_4_2022_To_5_4_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2022Member_h_obtA7-K0i33vHEmRb07w", "decimals": "-5", "lang": null, "name": "rzlt:ProfessionalFeesAndOfferingCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - SHAREHOLDERS' EQUITY - 2022 Pre-Funded Warrants (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "shortName": "SHAREHOLDERS' EQUITY - 2022 Pre-Funded Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_5_1_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrants2022Member_lwQ4NLzx5UeIDMHBVxXAUA", "decimals": "3", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_5_1_2022_q5vgTbXPlkWRAf_sK0z1yQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40704 - Disclosure - SHAREHOLDERS' EQUITY - Required Shareholder Approval (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "shortName": "SHAREHOLDERS' EQUITY - Required Shareholder Approval (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ClassBPreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2022Member_fdSJYEoDtEKDaYvCXG0dUA", "decimals": "-5", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ClassBPreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2022Member_94leI-sHuUWGG1rBPQqygw", "decimals": "3", "first": true, "lang": null, "name": "rzlt:PercentageOfLiquidationDamagesPayableNotObtainingStockholdersApproval", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40705 - Disclosure - SHAREHOLDERS' EQUITY - Registration Rights Agreement (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "shortName": "SHAREHOLDERS' EQUITY - Registration Rights Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ClassBPreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2022Member_94leI-sHuUWGG1rBPQqygw", "decimals": "3", "first": true, "lang": null, "name": "rzlt:PercentageOfLiquidationDamagesPayableNotObtainingStockholdersApproval", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DhQRZcNoTU6Ggjzv2ph9CA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DhQRZcNoTU6Ggjzv2ph9CA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "rzlt:ClassOfWarrantOrRightGranted", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40706 - Disclosure - SHAREHOLDERS' EQUITY - 2021 Underwritten Public Offering (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "shortName": "SHAREHOLDERS' EQUITY - 2021 Underwritten Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_10_15_2021_To_10_15_2021_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_r9OeV5q0CUS_hhEWY1xiqg", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40707 - Disclosure - SHAREHOLDERS' EQUITY - 2021 Pre-Funded Warrants (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "shortName": "SHAREHOLDERS' EQUITY - 2021 Pre-Funded Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrants2021Member_TZAAawoXs0C44DC6EVqaPQ", "decimals": null, "lang": "en-US", "name": "rzlt:MinimumPeriodForIncreaseOrDecreaseInOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2021Member_m150E7Adok-aqSqJp8eA1g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40708 - Disclosure - SHAREHOLDERS' EQUITY - 2021 Registered Direct Offering (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "shortName": "SHAREHOLDERS' EQUITY - 2021 Registered Direct Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_RegisteredDirectOffering2021Member_wcIVHwPGO0iVShLj06romw", "decimals": "2", "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_12_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_rzlt_EquityDistributionAgreementMember_PtO-APhqE0CmuJ0ijKNQVg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40709 - Disclosure - SHAREHOLDERS' EQUITY - Equity Distribution Agreement (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "shortName": "SHAREHOLDERS' EQUITY - Equity Distribution Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_12_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_rzlt_EquityDistributionAgreementMember_PtO-APhqE0CmuJ0ijKNQVg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_LincolnParkCapitalFundLlcPurchaseAgreementMember_z6Ixw0jcQU6HpqKqGdHsag", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40710 - Disclosure - SHAREHOLDERS' EQUITY - LPC Purchase Agreement (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "shortName": "SHAREHOLDERS' EQUITY - LPC Purchase Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_9_17_2021_To_9_17_2021_us-gaap_SubsidiarySaleOfStockAxis_rzlt_LincolnParkCapitalFundLlcPurchaseAgreementMember_zX1JCDWY50KWBcAjnQuBUw", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40711 - Disclosure - SHAREHOLDERS' EQUITY - Fiscal 2021 Equity Financing (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "shortName": "SHAREHOLDERS' EQUITY - Fiscal 2021 Equity Financing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_9_15_2020_To_9_15_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember_KqgryP_rhkyDAtEgmYhp2A", "decimals": "3", "lang": null, "name": "rzlt:AdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsPercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "INF", "first": true, "lang": null, "name": "rzlt:NumberOfActiveStockOptionPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_qEC6B9b_YkOoQMPN6tVOZg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "INF", "first": true, "lang": null, "name": "rzlt:NumberOfActiveStockOptionPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_qEC6B9b_YkOoQMPN6tVOZg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2021_1d3ahVSAdk-4BeZR1getXg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XiBh-oKcXEq0m6PFT7uO3w", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2021_1d3ahVSAdk-4BeZR1getXg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Warrants (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "lang": null, "name": "rzlt:ClassOfWarrantOrRightExpirations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Additional Information (Details)", "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - INCOME TAXES - Additional Information (Details)", "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "INCOME TAXES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - INCOME TAXES - Income Tax Expense (Details)", "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails", "shortName": "INCOME TAXES - Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)", "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails", "shortName": "INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_p9krFLk6g0iWadkLpfy2iA", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_QakuB0DnQkiN_OrYdPMIxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_9_15_2020_To_9_15_2020_us-gaap_RelatedPartyTransactionAxis_rzlt_HandokLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_rzlt_HandokInc.Member_qZ3jKOEfkk2eQ6CH59cdaA", "decimals": null, "lang": "en-US", "name": "rzlt:PharmaceuticalLicenseAgreementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details)", "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2022_sn2OOQgzT0q5gldW5c3pIA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details)", "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "shortName": "NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details)", "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "shortName": "NET LOSS PER SHARE - Anti-dilutive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xKAogNq6_U-hx4dknvJyZQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "As_Of_6_30_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_Oas1JVNK_0KbnOTl_z30NA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)", "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2020_To_6_30_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_VRCCTRb2fEymXw6G7YbImQ", "decimals": "-3", "lang": null, "name": "rzlt:FairValueOfEmbeddedDerivatives", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2022_To_7_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_rzlt_JulyTwoThousandTwentyTwoFinancingMember_bxjKArcKzEiG4UT5fgduXQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "Unit_Standard_USD_7gZjwPPMiEOiH5NO8DPIIQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - SUBSEQUENT EVENTS - July 2022 Financing (Details)", "role": "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails", "shortName": "SUBSEQUENT EVENTS - July 2022 Financing (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - LIQUIDITY", "role": "http://www.rezolutebio.com/role/DisclosureLiquidity", "shortName": "LIQUIDITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - LEASES", "role": "http://www.rezolutebio.com/role/DisclosureLeases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rzlt-20220630x10k.htm", "contextRef": "Duration_7_1_2021_To_6_30_2022_WeULd3wz60ihVvYYsowFOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 74, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rzlt_AccretionOfDebtDiscountAndIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value cost of accretion of debt discount and issuance costs.", "label": "Accretion Of Debt Discount And Issuance Costs", "negatedLabel": "Accretion of debt discount and issuance costs" } } }, "localname": "AccretionOfDebtDiscountAndIssuanceCosts", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_ActivesitePharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to ActiveSite Pharmaceuticals, Inc.", "label": "ActiveSite Pharmaceuticals, Inc" } } }, "localname": "ActivesitePharmaceuticalsIncMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_AdditionalAdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents additional amount incurred on gross proceeds od placement of shares", "label": "Additional Advisory Fee Payable On Gross Proceeds Received From Private Placements Percent", "terseLabel": "Additional Transaction fees (In percent)" } } }, "localname": "AdditionalAdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsPercent", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "percentItemType" }, "rzlt_AdjustmentToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityForAuthorizedShareDeficiency": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in additional paid in capital by reclassification of derivative liability for authorized share deficiency.", "label": "Adjustment To Additional Paid In Capital, Reclassification Of Derivative Liability For Authorized Share Deficiency", "negatedLabel": "Reclassification of derivative liabilities to equity upon cure of authorized share deficiency" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityForAuthorizedShareDeficiency", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rzlt_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsAndStockOptionsFromEquityToDerivativeLiabilityDueToAuthorizedShareDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the reclassification of Warrants and Stock Options from Equity to Derivative Liability Due to Authorized Share Deficiency.", "label": "Adjustments to Additional Paid in Capital Reclassification of warrants and stock options from equity to derivative liability due to authorized share deficiency", "negatedLabel": "Reclassification of warrants and stock options from equity to derivative liability due to authorized share deficiency", "terseLabel": "Reclassification of warrants and stock options from equity to derivative liability due to authorized share deficiency" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsAndStockOptionsFromEquityToDerivativeLiabilityDueToAuthorizedShareDeficiency", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rzlt_AdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of advisory fee payable on gross proceeds received from private placements.", "label": "Advisory Fee Payable on Gross Proceeds Received from Private Placements, Amount", "terseLabel": "Amount of advisory fee payable" } } }, "localname": "AdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsAmount", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_AdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of advisory fee payable on gross proceeds received from private placements.", "label": "Advisory Fee Payable on Gross Proceeds Received from Private Placements, Percent", "terseLabel": "Percent of advisory fee payable" } } }, "localname": "AdvisoryFeePayableOnGrossProceedsReceivedFromPrivatePlacementsPercent", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "percentItemType" }, "rzlt_AffiliatedInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to affiliated investors.", "label": "Affiliated Investors [Member]", "terseLabel": "Affiliated investors" } } }, "localname": "AffiliatedInvestorsMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rzlt_AggregateAnnualBaseSalaries": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate annual base salaries.", "label": "Aggregate Annual Base Salaries", "terseLabel": "Aggregate annual base salaries" } } }, "localname": "AggregateAnnualBaseSalaries", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_AllocationOfDebtProceedsToEmbeddedDerivativeObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information about allocation of debt proceeds to embedded derivative obligations.", "label": "Allocation Of Debt Proceeds To Embedded Derivative Obligations", "terseLabel": "Allocation of debt proceeds to embedded derivative obligations" } } }, "localname": "AllocationOfDebtProceedsToEmbeddedDerivativeObligations", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_AncillaryOfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents the information pertaining to ancillary office space", "label": "Ancillary Office Space" } } }, "localname": "AncillaryOfficeSpaceMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails" ], "xbrltype": "domainItemType" }, "rzlt_CashBalanceRequirement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the cash balance requirement subject to a control account in favor of the Lenders.", "label": "Cash Balance Requirement", "terseLabel": "Cash balance requirement" } } }, "localname": "CashBalanceRequirement", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_CertainOfficersEmployeesAndIndependentDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents certain officers , employees and independent directors", "label": "Certain officers , employees and independent directors" } } }, "localname": "CertainOfficersEmployeesAndIndependentDirectorsMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rzlt_ChangeInDomicilePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Accounting Policy, Change in Domicile and its regarding information.", "label": "Change in Domicile [Policy Text Block]", "terseLabel": "Change in Domicile" } } }, "localname": "ChangeInDomicilePolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_CharterRevisionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to charter revisions.", "label": "Charter Revision [Member]" } } }, "localname": "CharterRevisionMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables" ], "xbrltype": "domainItemType" }, "rzlt_ChiefExecutiveOfficerIndependentDirectorsAndEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Chief executive officer, independent directors and employees", "label": "Chief executive officer, independent directors and employees" } } }, "localname": "ChiefExecutiveOfficerIndependentDirectorsAndEmployeesMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rzlt_ClassBPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Class B pre-funded warrants.", "label": "Class B Warrants", "terseLabel": "Class B Pre-Funded Warrants" } } }, "localname": "ClassBPreFundedWarrantsMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights exercisable.", "label": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercisable price per share" } } }, "localname": "ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fee amount per share price that is required to be paid upon exercise of the warrants.", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Fee", "terseLabel": "Fee amount per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsFee", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_ClassOfWarrantOrRightExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised.", "label": "Class of Warrant or Right, Exercised", "terseLabel": "Warrants exercised" } } }, "localname": "ClassOfWarrantOrRightExercised", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails" ], "xbrltype": "sharesItemType" }, "rzlt_ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights expired.", "label": "Class of Warrant or Right, Expiration, Exercise Price of Warrants or Rights", "terseLabel": "Warrant expirations (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_ClassOfWarrantOrRightExpirations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights expired.", "label": "Class of Warrant or Right, Expirations", "negatedLabel": "Warrant expirations (In shares)" } } }, "localname": "ClassOfWarrantOrRightExpirations", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "sharesItemType" }, "rzlt_ClassOfWarrantOrRightGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of warrants granted during the period.", "label": "Class of Warrant or Right, Granted", "terseLabel": "Warrants granted (In shares)" } } }, "localname": "ClassOfWarrantOrRightGranted", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "rzlt_ClassOfWarrantOrRightGrantedExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights granted.", "label": "Class of Warrant or Right, Granted, Exercise Price of Warrants or Rights", "terseLabel": "Warrants granted (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightGrantedExercisePriceOfWarrantsOrRights", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued.", "label": "Class of Warrant or Right, Issued", "terseLabel": "Warrants issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "sharesItemType" }, "rzlt_ClassPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Class A pre-funded warrants.", "label": "Class A Warrants", "verboseLabel": "Class A pre-funded warrants" } } }, "localname": "ClassPreFundedWarrantsMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_ClinicalTrialAccrualsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on clinical trial accruals.", "label": "Clinical Trial Accruals [Policy Text Block]", "terseLabel": "Clinical Trial Accruals" } } }, "localname": "ClinicalTrialAccrualsPolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The line items identify information about the commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "rzlt_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This table lists the commitments and contingencies.", "label": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "rzlt_CommonStockDeficiencyOfRequiredSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of common shares below the required amount to be authorized causing a deficiency.", "label": "Common Stock, Deficiency Of Required Shares Authorized", "terseLabel": "Number of shares" } } }, "localname": "CommonStockDeficiencyOfRequiredSharesAuthorized", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "rzlt_CommonStockDeficiencyWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value per share of deficient shares.", "label": "Common Stock, Deficiency, Weighted Average Fair Value", "terseLabel": "Weighted average fair value per share" } } }, "localname": "CommonStockDeficiencyWeightedAverageFairValue", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_CommonStockFairValueDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the deficient common shares below the required amount to be authorized.", "label": "Common Stock, Fair Value, Deficiency", "terseLabel": "Fair value of derivative liability" } } }, "localname": "CommonStockFairValueDeficiency", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_CommonStockRequiredSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum number of common shares required to be authorized.", "label": "Common Stock, Required Shares Authorized" } } }, "localname": "CommonStockRequiredSharesAuthorized", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rzlt_CorporateHeadquartersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to lease agreement for corporate headquarters.", "label": "Corporate Headquarters" } } }, "localname": "CorporateHeadquartersMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "domainItemType" }, "rzlt_DebtDiscountsIncurredForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Debt discounts incurred for:" } } }, "localname": "DebtDiscountsIncurredForAbstract", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "rzlt_DebtInstrumentDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of total debt discount.", "label": "Debt Instrument, Discount", "terseLabel": "Total debt discount" } } }, "localname": "DebtInstrumentDiscount", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_DebtInstrumentExitFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the exit fee on the funded principal balance.", "label": "Debt Instrument, Exit Fee", "terseLabel": "Exit fee on the funded principal balance" } } }, "localname": "DebtInstrumentExitFee", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_DebtInstrumentFinancialAdvisoryAndLegalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of financial advisory and legal fee.", "label": "Debt Instrument, Financial Advisory and Legal Fees", "terseLabel": "Financial advisory and legal fees" } } }, "localname": "DebtInstrumentFinancialAdvisoryAndLegalFees", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_DebtInstrumentInterestRateVariablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable margin interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Variable Percentage", "terseLabel": "Variable margin rate" } } }, "localname": "DebtInstrumentInterestRateVariablePercentage", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_DebtInstrumentPercentageFinalFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of final fee.", "label": "Debt Instrument, Percentage, Final Fee", "terseLabel": "Final fee" } } }, "localname": "DebtInstrumentPercentageFinalFee", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_DebtInstrumentPercentageNonRefundableFacilityFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of non-refundable facility fee.", "label": "Debt Instrument, Percentage, Non-refundable Facility Fee", "verboseLabel": "Non-refundable facility fee" } } }, "localname": "DebtInstrumentPercentageNonRefundableFacilityFee", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_DebtInstrumentPrepaymentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the prepayment fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Prepayment Fee", "terseLabel": "Prepayment fee" } } }, "localname": "DebtInstrumentPrepaymentFee", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_DebtInstrumentPrepaymentFeeAmount": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The following information pertaining to the Debt Instrument Prepayment Fee Amount.", "label": "Debt Instrument Prepayment Fee Amount", "terseLabel": "Debt instrument prepayment fee amount", "verboseLabel": "Prepayment premium paid" } } }, "localname": "DebtInstrumentPrepaymentFeeAmount", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_DerivativeLiabilitiesFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of derivative liability.", "label": "Derivative Liabilities, Fair Value Adjustment", "terseLabel": "Non-cash gain from change in fair value of derivative liabilities" } } }, "localname": "DerivativeLiabilitiesFairValueAdjustment", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_DerivativeLiabilityForAuthorizedShareDeficiencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES" } } }, "localname": "DerivativeLiabilityForAuthorizedShareDeficiencyAbstract", "nsuri": "http://www.rezolutebio.com/20220630", "xbrltype": "stringItemType" }, "rzlt_DerivativeLiabilityForAuthorizedShareDeficiencyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the derivative liability for authorized share deficiency", "label": "Derivative Liability for Authorized Share Deficiency [Policy Text Block]", "terseLabel": "Derivative Liability for Authorized Share Deficiencies" } } }, "localname": "DerivativeLiabilityForAuthorizedShareDeficiencyPolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative liability for authorized share deficiency .", "label": "Derivative Liability for Authorized Share Deficiency [Text block]", "terseLabel": "DERIVATIVE LIABILITIES FOR AUTHORIZED SHARE DEFICIENCIES" } } }, "localname": "DerivativeLiabilityForAuthorizedShareDeficiencyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficiencies" ], "xbrltype": "textBlockItemType" }, "rzlt_DevelopmentAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development And License Agreement [Member]", "label": "Development And License Agreement [Member]" } } }, "localname": "DevelopmentAndLicenseAgreementMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalties.", "label": "Development and License Agreement, Royalties Percentage", "terseLabel": "Royalties percentage" } } }, "localname": "DevelopmentAndLicenseAgreementRoyaltiesPercentage", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "percentItemType" }, "rzlt_DilutiveSecuritiesEffectOnBasicEarningsPerShareDiscountOnIssuanceOfDerivativeLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from discount on issuance of derivative liability.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Discount On Issuance Of Derivative Liability", "terseLabel": "Underwriting discount on issuance of derivative" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareDiscountOnIssuanceOfDerivativeLiability", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainFromChangeInFairValueOfDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from gain from change in fair value of derivative liability.", "label": "Dilutive Securities, Effect On Basic Earnings Per Share, Gain From Change In Fair Value Of Derivative Liability", "terseLabel": "Gain from change in fair value of derivative liability" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareGainFromChangeInFairValueOfDerivativeLiability", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_DirectorsAndOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to directors and officers.", "label": "Directors and officers" } } }, "localname": "DirectorsAndOfficersMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "rzlt_EffectiveIncomeTaxRateReconciliationNonTaxableDerivativeGainsAmount": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to non-taxable derivative gains.", "label": "Effective Income Tax Rate Reconciliation, Non-Taxable Derivative Gains, Amount", "terseLabel": "Non-taxable derivative gains" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNonTaxableDerivativeGainsAmount", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_EffectiveIncomeTaxRateReconciliationStockOptionExpirations": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock option expiration.", "label": "Effective Income Tax Rate Reconciliation, Stock Option Expirations", "negatedLabel": "Stock option expirations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStockOptionExpirations", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_EmbeddedDerivativeAssociatedWithExitFeeAndPrepaymentFeeRelatedToTermLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of embedded derivative associated with the exit fee and prepayment fee related to the term A loan.", "label": "Embedded Derivative Associated With the Exit Fee and Prepayment Fee Related to the Term A Loan", "terseLabel": "Embedded derivative associated with the exit fee and prepayment fee related to the term A loan" } } }, "localname": "EmbeddedDerivativeAssociatedWithExitFeeAndPrepaymentFeeRelatedToTermLoan", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_EmployeeRetentionCreditFromFederalAndStateGovernmentsFinancialAssistanceCaresAct": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of employee retention credit from federal and state government, U.S, Financial assistance, CARES Act", "label": "Employee Retention Credit from Federal and State Governments Financial Assistance, CARES Act", "terseLabel": "Employee retention credit" } } }, "localname": "EmployeeRetentionCreditFromFederalAndStateGovernmentsFinancialAssistanceCaresAct", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "rzlt_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents employees", "label": "Employees" } } }, "localname": "EmployeesMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "rzlt_EmploymentAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to employment agreement.", "label": "Employment Agreements" } } }, "localname": "EmploymentAgreementsMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "rzlt_EquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents information about agreement between parties", "label": "Equity Distribution Agreement", "terseLabel": "Equity Distribution Agreement", "verboseLabel": "EDA with Oppco" } } }, "localname": "EquityDistributionAgreementMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_EquityFinancingCostCapitalizationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to capitalized equity financing costs. Includes, but is not limited to, commissions, legal fees and other costs.", "label": "Equity Financing Cost Capitalization Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "EquityFinancingCostCapitalizationPolicyPolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_ExpirationOfStockOptionsAndWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock options and warrants expired.", "label": "Expiration of Stock Options and Warrants", "terseLabel": "Expiration of stock options and warrants" } } }, "localname": "ExpirationOfStockOptionsAndWarrants", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails" ], "xbrltype": "sharesItemType" }, "rzlt_FairValueAdjustmentOfShares": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of shares of common stock.", "label": "Fair Value Adjustment of Shares", "terseLabel": "Fair value of shares of common stock issued for services" } } }, "localname": "FairValueAdjustmentOfShares", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_FairValueOfEmbeddedDerivatives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of embedded derivatives.", "label": "Fair Value of Embedded Derivatives", "terseLabel": "Fair value of embedded derivatives", "verboseLabel": "Fair value of embedded derivatives upon execution of Loan Agreement" } } }, "localname": "FairValueOfEmbeddedDerivatives", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails", "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_FairValueOfWarrantsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of warrant per share.", "label": "Fair Value of Warrants Per Share", "terseLabel": "Fair value of warrant per share" } } }, "localname": "FairValueOfWarrantsPerShare", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_FinalFeeObligationUnderDebtAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount final Fee obligation under debt agreement in non-cash investing and financing activity.", "label": "Final Fee Obligation Under Debt Agreement", "terseLabel": "Final Fee obligation under debt agreement" } } }, "localname": "FinalFeeObligationUnderDebtAgreement", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_Fiscal2021EquityFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Fiscal 2021 Equity Financing.", "label": "Fiscal 2021 Equity Financing [Member]" } } }, "localname": "Fiscal2021EquityFinancingMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "rzlt_FurnitureAndEquipmentReceivedAsInducementUnderOperatingLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of furniture and equipment received as inducement under operating lease.", "label": "Furniture and Equipment Received as Inducement Under Operating lease", "terseLabel": "Furniture and equipment received as inducement under operating lease" } } }, "localname": "FurnitureAndEquipmentReceivedAsInducementUnderOperatingLease", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_GainsLossesOnExtinguishmentOfDebtUnaccretedDiscount": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain/loss on amount, after accumulated amortization, of debt discount extinguished.", "label": "Gains Losses On Extinguishment Of Debt, Unaccreted Discount", "negatedLabel": "Other", "terseLabel": "Loss on extinguishment of debt, unaccreted discount" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtUnaccretedDiscount", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_GovernmentalAssistancePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Accounting policy of Governmental Assistance and its information.", "label": "Governmental Assistance [Policy Text Block]", "terseLabel": "Governmental Assistance" } } }, "localname": "GovernmentalAssistancePolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_HandokInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Handok, Inc. [Member]", "label": "Handok, Inc. [Member]", "terseLabel": "Handok, Inc." } } }, "localname": "HandokInc.Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rzlt_HandokLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Handok License agreement", "label": "Handok License Agreement [Member]", "terseLabel": "Handok License Agreement" } } }, "localname": "HandokLicenseAgreementMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rzlt_IncreaseDecreaseInLicenseFeePayable": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents the increase or decrease in license fee payable.", "label": "Increase decrease In License Fee Payable", "terseLabel": "Decrease in license fees payable to XOMA" } } }, "localname": "IncreaseDecreaseInLicenseFeePayable", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_IrcSection382OwnershipChangesNotOccurMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the scenario if IRC Section 382 ownership changes do not occur.", "label": "IRC Section382 Ownership Changes Not Occur [Member]", "terseLabel": "IRC Section 382 ownership changes do not occur" } } }, "localname": "IrcSection382OwnershipChangesNotOccurMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rzlt_IrcSection382OwnershipChangesOccursMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the scenario if IRC Section 382 ownership changes occurs.", "label": "IRC Section382 Ownership Changes Occurs [Member]", "terseLabel": "IRC Section 382 ownership changes occurs" } } }, "localname": "IrcSection382OwnershipChangesOccursMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rzlt_JulyTwoThousandTwentyTwoFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to July 2022 financing.", "label": "July 2022 Financing" } } }, "localname": "JulyTwoThousandTwentyTwoFinancingMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "domainItemType" }, "rzlt_June2022GrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to June 2022 grants.", "label": "June 2022 Grants" } } }, "localname": "June2022GrantsMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedFurnitureAndEquipmentAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of lease allowance provided for furniture and equipment.", "label": "Lessee Operating Lease Lease Not Yet Commenced Furniture And Equipment Allowance", "terseLabel": "Purchase of furniture and equipment" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedFurnitureAndEquipmentAllowance", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease yet to commence.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability", "terseLabel": "Total base rent payments", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiability", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityPaymentDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/a.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, Payment, Due [Abstract]", "terseLabel": "Future payments under this operating lease agreement" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityPaymentDueAbstract", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "stringItemType" }, "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedMonthlyAverageBaseRentPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of average base rent payable monthly.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Monthly Average Base Rent Payable", "terseLabel": "Average base rent payable in cash per month" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedMonthlyAverageBaseRentPayable", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedOperatingLeaseSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the amount of space to be leased.", "label": "Lessee, Operating Lease, Lease Not yet Commenced Operating Lease, Space", "terseLabel": "Operating lease not yet commenced for space" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOperatingLeaseSpace", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "areaItemType" }, "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedRentAbatementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The operating lease rent abatement period.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Rent Abatement Period", "terseLabel": "Period of rent abatement" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRentAbatementPeriod", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "durationItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease not yet commenced liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Not Yet Commenced Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of future payments under operating lease not yet commenced" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityMaturityTableTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidAfterYearFive": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": 6.0, "parentTag": "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease not yet commenced to be paid in after Fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Not Yet Commenced Liability, to be Paid, After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidAfterYearFive", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": 2.0, "parentTag": "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease not yet commenced to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Not Yet Commenced Liability To Be Paid Next Twelve Months", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidNextTwelveMonths", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearFive": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": 5.0, "parentTag": "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease not yet commenced to be paid in fifth fiscal year when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Not Yet Commenced Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearFive", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearFour": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": 4.0, "parentTag": "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease not yet commenced to be paid in fourth fiscal year when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Not Yet Commenced Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearFour", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearThree": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": 3.0, "parentTag": "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease not yet commenced to be paid in third fiscal year when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Not Yet Commenced Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearThree", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearTwo": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails": { "order": 1.0, "parentTag": "rzlt_LesseeOperatingLeaseLeaseNotYetCommencedLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease not yet commenced to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Not Yet Commenced Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearTwo", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LesseeOperatingLeaseNumberOfOptionsToExtend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of times the lease agreement provides an option to extend lease term.", "label": "Lessee Operating Lease, Number Of Options To Extend" } } }, "localname": "LesseeOperatingLeaseNumberOfOptionsToExtend", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "integerItemType" }, "rzlt_LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of carrying value of ROU assets and operating lease liabilities.", "label": "Lessee, Operating Lease, Right Of Use Assets And Operating Lease Liabilities", "terseLabel": "Schedule of carrying value of ROU assets and operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "rzlt_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "LICENSE AGREEMENTS" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://www.rezolutebio.com/20220630", "xbrltype": "stringItemType" }, "rzlt_LicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about License agreements.", "label": "LICENSE AGREEMENTS [Text block]", "terseLabel": "LICENSE AGREEMENTS" } } }, "localname": "LicenseAgreementsTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "rzlt_LincolnParkCapitalFundLlcPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Lincoln Park Capital Fund, LLC (LPC) Purchase Agreement.", "label": "Lincoln Park Capital Fund, LLC Purchase Agreement [Member]" } } }, "localname": "LincolnParkCapitalFundLlcPurchaseAgreementMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_LiquidationDamagesPayableOnNotObtainingStockholdersApproval": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of liquidation damages payable if company does not obtain stockholders approval.", "label": "Liquidation Damages Payable On Not Obtaining Stockholders Approval", "terseLabel": "Liquidation damages payable if company does not obtain stockholders approval" } } }, "localname": "LiquidationDamagesPayableOnNotObtainingStockholdersApproval", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_LiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LIQUIDITY" } } }, "localname": "LiquidityAbstract", "nsuri": "http://www.rezolutebio.com/20220630", "xbrltype": "stringItemType" }, "rzlt_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to loan and security agreement.", "label": "Loan and security agreement" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "domainItemType" }, "rzlt_MaximumAmountOfMilestoneEvents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of milestone event which need to occur for making specific range of milestone payment.", "label": "Maximum Amount of Milestone Events" } } }, "localname": "MaximumAmountOfMilestoneEvents", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_MaximumNumberOfAdditionalSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the maximum number of additional shares offered.", "label": "Maximum Number Of Additional Shares Issued", "terseLabel": "Maximum number of additional shares issued" } } }, "localname": "MaximumNumberOfAdditionalSharesIssued", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "rzlt_MaximumNumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum number of shares offered.", "label": "Maximum Number Of Shares Purchased", "terseLabel": "Maximum number of shares purchased" } } }, "localname": "MaximumNumberOfSharesPurchased", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails" ], "xbrltype": "sharesItemType" }, "rzlt_MaximumPurchasePriceCommittedObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum amount of purchase price.", "label": "Maximum Purchase Price Committed Obligation", "terseLabel": "Maximum purchase price committed obligation" } } }, "localname": "MaximumPurchasePriceCommittedObligation", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_MilestoneClosingPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone payment made during the period.", "label": "Milestone Closing Payment", "terseLabel": "Milestone closing payment" } } }, "localname": "MilestoneClosingPayment", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_MinimalStockPriceForVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "it represents closing stock price of vesting options", "label": "Minimal Stock Price For Vesting", "terseLabel": "Minimal stock price for vesting" } } }, "localname": "MinimalStockPriceForVesting", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "rzlt_MinimumPeriodForIncreaseOrDecreaseInOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for increase decrease of ownership percentage in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Minimum Period For Increase Or Decrease In Ownership Percentage", "terseLabel": "Minimum Period For Increase Or Decrease In Ownership Percentage" } } }, "localname": "MinimumPeriodForIncreaseOrDecreaseInOwnershipPercentage", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails" ], "xbrltype": "durationItemType" }, "rzlt_MonthlyOperatingLeaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of monthly operating lease rent.", "label": "Monthly Operating Lease Rent" } } }, "localname": "MonthlyOperatingLeaseRent", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount representing the non cash lease expense.", "label": "Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_NumberOfActiveStockOptionPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of active stock option plans.", "label": "Number Of Active Stock Option Plans", "terseLabel": "Number of active stock option plans" } } }, "localname": "NumberOfActiveStockOptionPlans", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "integerItemType" }, "rzlt_NumberOfConsecutiveBusinessDaysForSelectingThreeLowestClosingSalePrices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of lowest closing sale prices for determining regular purchase share price.", "label": "Number of Consecutive Business Days for Selecting Three Lowest Closing Sale Prices", "terseLabel": "Number of consecutive business days for selecting three lowest closing sale prices" } } }, "localname": "NumberOfConsecutiveBusinessDaysForSelectingThreeLowestClosingSalePrices", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails" ], "xbrltype": "durationItemType" }, "rzlt_NumberOfEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to number of employees.", "label": "Number of Employees", "terseLabel": "Number of employee" } } }, "localname": "NumberOfEmployees", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "rzlt_NumberOfLowestClosingSalePricesForDeterminingRegularPurchaseSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of lowest closing sale prices taken into consideration for determining regular purchase share price.", "label": "Number of Lowest Closing Sale Prices for Determining Regular Purchase Share Price", "terseLabel": "Number of lowest closing sale prices for determining regular purchase share price" } } }, "localname": "NumberOfLowestClosingSalePricesForDeterminingRegularPurchaseSharePrice", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails" ], "xbrltype": "integerItemType" }, "rzlt_NumberOfOfficers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to number of officers.", "label": "Number of Officers", "terseLabel": "Number of officers" } } }, "localname": "NumberOfOfficers", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "rzlt_NumberOfOfficersAndOtherEmployeesSurrenderedTheirAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of officers and other employees surrendered their awards.", "label": "Number of Officers and Other Employees Surrendered Their Awards", "terseLabel": "Number of officers and other employees surrendered their awards" } } }, "localname": "NumberOfOfficersAndOtherEmployeesSurrenderedTheirAwards", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rzlt_NumberOfSharesSubjectToDeficiencyRequiredToSettleInCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares subject to the deficiency, required to settle in cash.", "label": "Number Of Shares Subject To The Deficiency, Required To Settle In Cash", "terseLabel": "Shares subject to the deficiency, required to settle in cash" } } }, "localname": "NumberOfSharesSubjectToDeficiencyRequiredToSettleInCash", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails" ], "xbrltype": "sharesItemType" }, "rzlt_NumberOfWhollyOwnedSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of wholly owned subsidiaries.", "label": "Number of Wholly Owned Subsidiaries" } } }, "localname": "NumberOfWhollyOwnedSubsidiaries", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "rzlt_OperatingLeaseSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to total square feet of leased space.", "label": "Operating Lease Space", "terseLabel": "Lease space" } } }, "localname": "OperatingLeaseSpace", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "areaItemType" }, "rzlt_OtherOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related to other offering costs", "label": "Other Offering Costs", "verboseLabel": "Other offering costs" } } }, "localname": "OtherOfferingCosts", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_PayablesForDeferredOfferingCostsSubsequentlyChargedToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of payables for deferred offering costs subsequently charged to additional paid-in capital.", "label": "Payables For Deferred Offering Costs Subsequently Charged To Additional Paid In Capital", "terseLabel": "Payables for deferred offering costs subsequently charged to additional paid-in capital" } } }, "localname": "PayablesForDeferredOfferingCostsSubsequentlyChargedToAdditionalPaidInCapital", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_PaymentsForProfessionalFeesAndOtherOfferingCosts": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Professional Fees And Other Offering Costs", "label": "Payments For Professional Fees And Other Offering Costs", "negatedLabel": "Payment of commissions and other deferred offering costs" } } }, "localname": "PaymentsForProfessionalFeesAndOtherOfferingCosts", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rzlt_PercentageOfAnnualTargetBonuses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of annual target bonuses.", "label": "Percentage of Annual Target Bonuses", "terseLabel": "Annual target bonuses (as a percent)" } } }, "localname": "PercentageOfAnnualTargetBonuses", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "rzlt_PercentageOfEntitySSharesHeldByInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of entity's shares held by investors.", "label": "Percentage Of Entity's Shares Held By Investors", "terseLabel": "Percentage of entity's shares held by investors" } } }, "localname": "PercentageOfEntitySSharesHeldByInvestors", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_PercentageOfLiquidationDamagesPayableNotObtainingStockholdersApproval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of liquidation damages payable if company does not obtain stockholders approval.", "label": "Percentage of Liquidation Damages Payable, Not Obtaining Stockholders Approval", "terseLabel": "Percentage of liquidation damages payable if company does not obtain stockholders approval" } } }, "localname": "PercentageOfLiquidationDamagesPayableNotObtainingStockholdersApproval", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_PharmaceuticalLicenseAgreementMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments to be incurred for the approval of license.", "label": "Pharmaceutical License Agreement, Milestone Payment", "terseLabel": "Milestone payments" } } }, "localname": "PharmaceuticalLicenseAgreementMilestonePayment", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_PharmaceuticalLicenseAgreementMilestonePaymentEarned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments earned by the entity.", "label": "Pharmaceutical License Agreement Milestone Payment Earned", "terseLabel": "Milestone payments earned" } } }, "localname": "PharmaceuticalLicenseAgreementMilestonePaymentEarned", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_PharmaceuticalLicenseAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of pharmaceutical license agreement in years.", "label": "Pharmaceutical License Agreement, Term", "terseLabel": "License term (in years)" } } }, "localname": "PharmaceuticalLicenseAgreementTerm", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "rzlt_PharmaceuticalLicenseAgreementTransferPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of transfer price on sale of products.", "label": "Pharmaceutical License Agreement, Transfer Price", "terseLabel": "Transfer price (in percent)" } } }, "localname": "PharmaceuticalLicenseAgreementTransferPrice", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rzlt_Phase2ClinicalTrialRz358Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 2 Clinical Trial RZ358" } } }, "localname": "Phase2ClinicalTrialRz358Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_Phase2ClinicalTrialRz402Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 2 Clinical Trial RZ402" } } }, "localname": "Phase2ClinicalTrialRz402Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_Phase3ClinicalTrialRz358Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 3 Clinical Trial Rz 358 [Member].", "label": "Phase 3 Clinical Trial Rz 358" } } }, "localname": "Phase3ClinicalTrialRz358Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_PreFundedWarrants2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2021 warrants.", "label": "Pre-Funded Warrants 2021 [Member]", "terseLabel": "2021 Pre-Funded Warrants" } } }, "localname": "PreFundedWarrants2021Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_PreFundedWarrants2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2022 warrants.", "label": "2022 Pre-Funded Warrants" } } }, "localname": "PreFundedWarrants2022Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees.", "label": "Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions", "terseLabel": "Net cash proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_ProceedsFromIssuanceOfPrivatePlacementNetOfAdvisoryFeesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of proceeds from issuance of private placement net of advisory fees payable.", "label": "Proceeds from Issuance of Private Placement, Net of Advisory Fees Payable", "terseLabel": "Net proceeds from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacementNetOfAdvisoryFeesPayable", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_ProfessionalFeesAndOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents amount of professional fees and other offering cots", "label": "Professional Fees And Offering Cost", "terseLabel": "Professional fees and offering costs" } } }, "localname": "ProfessionalFeesAndOfferingCost", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_RegisteredDirectOffering2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to registered direct offering 2021.", "label": "Registered Direct Offering 2021 [Member]", "terseLabel": "2021 Registered Direct Offering" } } }, "localname": "RegisteredDirectOffering2021Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_RegisteredDirectOffering2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to registered direct offering 2022.", "label": "Registered Direct Offering 2022", "terseLabel": "2022 Registered Direct Offering" } } }, "localname": "RegisteredDirectOffering2022Member", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to registered direct offering.", "label": "Registered Direct Offering" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rzlt_RemainderOfUnrestrictedEquitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of Remainder Of Unrestricted Equity Securities.", "label": "Remainder Of Unrestricted Equity Securities", "terseLabel": "Remainder of unrestricted equity securities" } } }, "localname": "RemainderOfUnrestrictedEquitySecurities", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_RepaymentsOfDebtFinalFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period for the final fee related to the repayment of the principal balance of short-term and long-term debt.", "label": "Repayments Of Debt, Final Fee" } } }, "localname": "RepaymentsOfDebtFinalFee", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_RepaymentsOfDebtPrincipalBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of the principal balance of short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments Of Debt, Principal Balance" } } }, "localname": "RepaymentsOfDebtPrincipalBalance", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy for reverse stock split", "label": "Reverse Stock Split [ Policy Text Block]", "terseLabel": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_ReverseStockSplitRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents information about percentage of common stock reverse split ratio", "label": "Reverse Stock Split Ratio" } } }, "localname": "ReverseStockSplitRatio", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "decimalItemType" }, "rzlt_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the risks and uncertainties during the reporting period.", "label": "Risks and Uncertainties [Policy Text Block]", "verboseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to after the clinical and regulatory milestones.", "label": "Scenario, After Clinical and Regulatory Milestones [Member]", "terseLabel": "After Clinical and Regulatory Milestones" } } }, "localname": "ScenarioAfterClinicalAndRegulatoryMilestonesMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to upon the clinical and regulatory milestones.", "label": "Scenario, Upon Clinical and Regulatory Milestones [Member]", "terseLabel": "Upon Clinical and Regulatory Milestones" } } }, "localname": "ScenarioUponClinicalAndRegulatoryMilestonesMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "rzlt_ScheduleOfEquityShareDeficiencyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity components associated with the derivative liability.", "label": "Schedule Of Equity Share Deficiency [Table Text Block]", "terseLabel": "Summary of Share Deficiencies" } } }, "localname": "ScheduleOfEquityShareDeficiencyTableTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables" ], "xbrltype": "textBlockItemType" }, "rzlt_ScheduleOfEquityShareDeficiencyValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock deficiencies.", "label": "Schedule Of Equity Share Deficiency Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of the Fair Value Assumptions of Share Deficiencies" } } }, "localname": "ScheduleOfEquityShareDeficiencyValuationAssumptionsTableTextBlock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables" ], "xbrltype": "textBlockItemType" }, "rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMarketPriceOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market price of Common Stock", "terseLabel": "Market price of Common Stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMarketPriceOfCommonStock", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "perShareItemType" }, "rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAggregateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, granted in period, aggregate fair value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Aggregate Fair Value", "terseLabel": "Aggregate fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAggregateFairValue", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_ShareBasedPaymentArrangementExpenseRelatingToCancelledShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for awards surrendered for cancellation under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense Relating to Cancelled Shares", "terseLabel": "Previously unrecognized compensation cost charged to expense on the date of cancellation" } } }, "localname": "ShareBasedPaymentArrangementExpenseRelatingToCancelledShares", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of the number of shares authorized, outstanding, and available for future grants under stock option.", "label": "Share-based Payment Arrangement, Option, Shares Authorized, Outstanding, and Available for Future Grants", "terseLabel": "Schedule of the Number of Shares Authorized, Outstanding, and Available for Future Grants Under Stock Option" } } }, "localname": "ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "rzlt_StockCommittedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock committed during the period.", "label": "Stock Committed During Period, Shares, New Issues", "terseLabel": "Commitment shares issued", "verboseLabel": "Commitment shares issued under LPC Purchase Agreement (in shares)" } } }, "localname": "StockCommittedDuringPeriodSharesNewIssues", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rzlt_StockCommittedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock committed during the period.", "label": "Stock Committed During Period, Value, New Issues", "terseLabel": "Commitment shares issued under LPC Purchase Agreement" } } }, "localname": "StockCommittedDuringPeriodValueNewIssues", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rzlt_TermBLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Term B loan.", "label": "Term B loan" } } }, "localname": "TermBLoanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "domainItemType" }, "rzlt_TermLoanBAndCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Term loan B and C.", "label": "Term B and C Loan" } } }, "localname": "TermLoanBAndCMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "domainItemType" }, "rzlt_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Term A loan.", "label": "Term A loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "domainItemType" }, "rzlt_UnderwritersDiscountExpensed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of underwriters discount expensed during the reporting period.", "label": "Underwriters Discount Expensed", "terseLabel": "Underwriters discount expensed" } } }, "localname": "UnderwritersDiscountExpensed", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_UnderwritersOptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters Option Period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Underwriters Option Period", "terseLabel": "Underwriters option period" } } }, "localname": "UnderwritersOptionPeriod", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails" ], "xbrltype": "durationItemType" }, "rzlt_UnderwritingDiscountsAndCommissions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of underwriting discounts and commissions.", "label": "Underwriting Discounts and Commissions", "terseLabel": "Underwriting discounts and commissions ( In percentage)" } } }, "localname": "UnderwritingDiscountsAndCommissions", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails" ], "xbrltype": "percentItemType" }, "rzlt_UnderwritingDiscountsAndCommissionsExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs for underwriter discounts, commissions and other fees.", "label": "Underwriting Discounts And Commissions Expense", "terseLabel": "Underwriting discounts and commissions expense" } } }, "localname": "UnderwritingDiscountsAndCommissionsExpense", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "monetaryItemType" }, "rzlt_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to underwritten Public Offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "2021 Underwritten Public Offering" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "rzlt_WarrantExercisableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant exercisable term.", "label": "Warrant Exercisable Term", "terseLabel": "Warrant exercisable term" } } }, "localname": "WarrantExercisableTerm", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "durationItemType" }, "rzlt_WarrantsDesignatedPercentageElectedByHolder": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of warrants designated by holder.", "label": "Warrants Designated Percentage Elected By Holder", "terseLabel": "Warrants Designated Percentage Elected By Holder" } } }, "localname": "WarrantsDesignatedPercentageElectedByHolder", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails" ], "xbrltype": "percentItemType" }, "rzlt_WarrantsExercisedOrGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised or granted.", "label": "Warrants Exercised or Granted", "terseLabel": "Warrants granted or exercised" } } }, "localname": "WarrantsExercisedOrGranted", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "sharesItemType" }, "rzlt_XomaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "XOMA Corporation [Member]", "label": "XOMA Corporation [Member]" } } }, "localname": "XomaCorporationMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_XomaLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xoma License Agreement [Member]", "label": "Xoma License Agreement [Member]" } } }, "localname": "XomaLicenseAgreementMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_XomaUsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "XOMA (US) LLC [Member]", "label": "XOMA (US) LLC [Member]" } } }, "localname": "XomaUsLlcMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "rzlt_Year2015PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2015 plan.", "label": "2015 Plan" } } }, "localname": "Year2015PlanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "rzlt_Year2016PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2016 plan.", "label": "2016 Plan" } } }, "localname": "Year2016PlanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "rzlt_Year2019PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to year 2019 plan.", "label": "2019 Plan" } } }, "localname": "Year2019PlanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "rzlt_Year2021PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to year 2021 plan.", "label": "2021 Plan" } } }, "localname": "Year2021PlanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "rzlt_Year2021StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2021 Stock Incentive Plan.", "label": "2021 plan" } } }, "localname": "Year2021StockIncentivePlanMember", "nsuri": "http://www.rezolutebio.com/20220630", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r36", "r76", "r77", "r178", "r221" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r156", "r157", "r158", "r159", "r177", "r220", "r250", "r252", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r455", "r457", "r477", "r478" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r156", "r157", "r158", "r159", "r177", "r220", "r250", "r252", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r455", "r457", "r477", "r478" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "label": "Officer" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r150", "r156", "r157", "r158", "r159", "r177", "r220", "r247", "r250", "r252", "r286", "r287", "r288", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r455", "r457", "r477", "r478" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r150", "r156", "r157", "r158", "r159", "r177", "r220", "r247", "r250", "r252", "r286", "r287", "r288", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r455", "r457", "r477", "r478" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r476" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r476" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r35", "r36", "r76", "r77", "r178", "r221" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r89", "r94", "r155", "r251" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r139", "r140", "r245", "r246", "r456", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r139", "r140", "r245", "r246", "r456", "r463", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r89", "r94", "r155", "r251", "r412" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r141", "r403" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Insurance, Current", "terseLabel": "Insurance premiums" } } }, "localname": "AccruedInsuranceCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r8", "r147" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "SUPPLEMENTAL FINANCIAL INFORMATION" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r81", "r82", "r83", "r297", "r298", "r299", "r358" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r254", "r301", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r234", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Advisory fees, Underwriting commissions and other offering costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r173", "r234", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Fair value of warrants issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Compensation cost" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r48", "r59", "r197", "r376" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "negatedLabel": "Underwriting discount on issuance of derivative", "terseLabel": "Underwriting discount on issuance of derivative" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r10", "r73", "r131", "r133", "r137", "r143", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r335", "r340", "r367", "r407", "r409", "r435", "r446" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Carrying value of right-of-use assets and operating lease liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r22", "r73", "r143", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r335", "r340", "r367", "r407", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r6", "r61" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of fiscal year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r55", "r61", "r67" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of fiscal year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of fiscal year", "totalLabel": "Total cash, cash equivalents and restricted cash, end of fiscal year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r55", "r368" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r14", "r15", "r16", "r70", "r73", "r99", "r100", "r105", "r108", "r110", "r118", "r119", "r120", "r143", "r162", "r166", "r167", "r168", "r171", "r172", "r218", "r219", "r223", "r227", "r234", "r367", "r487" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r243", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "periodEndLabel": "Weighted average exercise price (Per share)", "periodStartLabel": "Weighted average exercise price( Per share)", "terseLabel": "Warrant price (per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Pre-funded warrants to purchase shares of common stock", "verboseLabel": "Number of shares of common stock called by warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, fiscal year (In shares)", "periodStartLabel": "Warrants outstanding, beginning of fiscal year (In shares)", "terseLabel": "Warrants outstanding (In shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r243", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r439", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Notes 3, 4, 7, 10 and 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r152", "r153", "r154", "r160", "r464" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for issuance", "verboseLabel": "Shares reserved for purchase" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r81", "r82", "r358" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityChangesInAuthorizedCapitalStockDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r234" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 100,000 and 40,000 shares authorized as of June 30, 2022, and 2021, respectively; 33,582 and 8,352 shares issued and outstanding as of June 30, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r68", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOAN AND SECURITY AGREEMENT" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r69", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r191", "r198", "r199", "r201", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "LOAN AND SECURITY AGREEMENT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r72", "r79", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r204", "r205", "r206", "r207", "r378", "r436", "r437", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Facility Fee and Final Fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r28", "r203", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r28", "r175" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r30", "r72", "r79", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r204", "r205", "r206", "r207", "r378" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r72", "r79", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r200", "r204", "r205", "r206", "r207", "r235", "r238", "r239", "r240", "r376", "r377", "r378", "r379", "r444" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r187", "r376", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "verboseLabel": "Debt discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r64", "r65", "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Payables for debt issuance costs" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt Discounts and Issuance Costs" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "verboseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r316" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred income tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r318" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred income tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "verboseLabel": "Deferred income tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r321", "r322" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "NOL carryforwards", "verboseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "NOL carryforwards does not expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "NOL carryforwards begin to expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r321", "r322" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "verboseLabel": "Accrued expenses and other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r321", "r322" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "verboseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r321", "r322" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Other", "verboseLabel": "Start-up and organizational expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r317" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance for deferred income tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Total contributions by the company" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contributions (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r9" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits and other" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r59", "r145" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense related to property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r59", "r145" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Embedded derivative liability" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Non-operating loss on change in fair value of embedded derivative" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r36", "r349", "r352", "r353", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r78", "r345", "r346", "r347", "r348", "r356" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Embedded Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r257", "r258", "r292", "r293", "r295", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION AND WARRANTS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r44", "r86", "r87", "r88", "r89", "r90", "r96", "r99", "r108", "r109", "r110", "r114", "r115", "r359", "r360", "r441", "r453" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share - basic (in dollars per share)", "verboseLabel": "Net loss per share of common stock - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r44", "r86", "r87", "r88", "r89", "r90", "r99", "r108", "r109", "r110", "r114", "r115", "r359", "r360", "r441", "r453" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share - diluted (in dollars per share)", "verboseLabel": "Net loss per share of common stock - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r351" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative liabilities" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected to be recognized over a remaining weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "verboseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r40", "r41", "r42", "r81", "r82", "r83", "r85", "r91", "r93", "r117", "r144", "r234", "r241", "r297", "r298", "r299", "r324", "r325", "r358", "r369", "r370", "r371", "r372", "r373", "r374", "r397", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityContractMember": { "auth_ref": [ "r36", "r248", "r354" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to share prices.", "label": "Equity Contract [Member]" } } }, "localname": "EquityContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r59", "r211" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Fair value of warrants issued for services" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r363", "r366" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r363", "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in the Fair Value of the Company's Derivative Liabilities, Fair Value, Level 3 Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Loss from change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r349" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Gain from change in fair value of derivative liabilities, net", "terseLabel": "Gain from change in fair value of derivative liabilities, net" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r59", "r208", "r209" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Loss on extinguishment of loan agreement", "verboseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt [Abstract]", "terseLabel": "Loss on extinguishment of Loan Agreement" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r149", "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r74", "r312", "r314", "r320", "r326", "r328", "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r75", "r92", "r93", "r130", "r310", "r327", "r329", "r454" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r39", "r308", "r309", "r314", "r315", "r319", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r311" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r307", "r311" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Impact of reduction in Colorado tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r311" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax benefit at statutory US federal rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r311" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Non-deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r311" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r311" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "Income tax benefit attributable to US states" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r58" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase (decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r58" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Increase (decrease) in other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r58" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Increase prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "verboseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "verboseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r53", "r56", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Code (\"IRC\")" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of operating lease expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASES" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to extend the lease" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Period of average base rent payable in cash for lease term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of Lessee operating lease liability maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r394" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r394" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r394" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r73", "r134", "r143", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r336", "r340", "r341", "r367", "r407", "r408" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r73", "r143", "r367", "r409", "r438", "r449" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Equity", "terseLabel": "Liabilities and Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r27", "r73", "r143", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r336", "r340", "r341", "r367", "r407", "r408", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Contractual rate" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r188", "r202", "r204", "r205", "r437", "r447" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt", "verboseLabel": "Long term debt, net of discount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Exercise price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Dividend rate" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Remaining contractual term (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Historical volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Market price of common stock" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r121", "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "verboseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing Activities", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r55", "r57", "r60" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities", "verboseLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r37", "r38", "r42", "r43", "r60", "r73", "r84", "r86", "r87", "r88", "r89", "r92", "r93", "r106", "r131", "r132", "r135", "r136", "r138", "r143", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r360", "r367", "r440", "r452" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r86", "r87", "r88", "r89", "r96", "r97", "r107", "r110", "r131", "r132", "r135", "r136", "r138" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss for calculation of basic net loss per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Calculation of Numerators:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r98", "r101", "r102", "r103", "r104", "r107", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss for the calculation of diluted net loss per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Non-operating income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r131", "r132", "r135", "r136", "r138" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Future lease payments related to operating lease agreements" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r381" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "totalLabel": "Total", "verboseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Operating lease liabilities:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r381" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r381" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r383", "r389" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r380" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "netLabel": "Right-of-use assets", "verboseLabel": "Right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r392", "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Operating lease weighted average discount rate percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r391", "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term under operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r80", "r95", "r129", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r26", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Accrued clinical and other" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r52" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt discount and issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15", "r218" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityChangesInAuthorizedCapitalStockDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15", "r218" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r49" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuances of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "verboseLabel": "Gross proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r49" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from warrants issued" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds from sale of equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfDebt": { "auth_ref": [], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.", "label": "Proceeds from (Repayments of) Debt", "terseLabel": "Gross proceeds from Loan Agreement" } } }, "localname": "ProceedsFromRepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r37", "r38", "r42", "r54", "r73", "r84", "r92", "r93", "r131", "r132", "r135", "r136", "r138", "r143", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r334", "r338", "r339", "r342", "r343", "r360", "r367", "r442" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r7", "r146" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Office furniture and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r148", "r409", "r443", "r450" ], "calculation": { "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r148", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r249", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r249", "r400", "r401", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r249", "r400", "r404", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r398", "r399", "r401", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r51" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Prepayment of contractual obligations under Loan Agreement, including prepayment fee", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "License Agreements" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r304", "r421", "r479" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r241", "r409", "r448", "r461", "r462" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r81", "r82", "r83", "r85", "r91", "r93", "r144", "r297", "r298", "r299", "r324", "r325", "r358", "r458", "r460" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r390", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Right-of-use assets acquired in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScenarioPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The scenario under which facts represent plans as distinct from actual.", "label": "Plan" } } }, "localname": "ScenarioPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Potential Common Stock Equivalents were Excluded from the Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of Share-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFuturePaymentsOfLeaseYetToCommenceDetails", "http://www.rezolutebio.com/role/DisclosureLeasesHeadquartersLeaseDetails", "http://www.rezolutebio.com/role/DisclosureLeasesOfficeSpaceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r402", "r404" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r253", "r255", "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r262", "r277", "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of the Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of the Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionTable": { "auth_ref": [ "r212", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Schedule of the description and the details of all terms for each outstanding financial instrument and each settlement option, including: a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, \"the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share\") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable. g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments is disclosed separately from the amount of retained earnings or accumulated deficit).", "label": "Schedule of Financial Instruments Subject to Mandatory Redemption [Table]" } } }, "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r14", "r15", "r16", "r70", "r118", "r119", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r243", "r256" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r58" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHARE-BASED COMPENSATION AND WARRANTS" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Historical volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Weighted Average Remaining Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "terseLabel": "Number of shares surrendered for cancellation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of fiscal year", "periodStartLabel": "Outstanding, beginning of fiscal year", "terseLabel": "Number of shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of fiscal year", "periodStartLabel": "Outstanding, beginning of fiscal year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Time-based vesting [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Hybrid Vesting [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r261", "r283", "r284", "r285", "r286", "r289", "r300", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Price per share", "verboseLabel": "Purchase price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "verboseLabel": "Market price of common stock on grant date" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining contractual term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "verboseLabel": "Estimated fair value of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested, end of fiscal year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, end of fiscal year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issue price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionBySettlementTermsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Line Items]" } } }, "localname": "SharesSubjectToMandatoryRedemptionBySettlementTermsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsOfClassBPreFundedWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r70", "r73", "r99", "r100", "r105", "r108", "r110", "r118", "r119", "r120", "r143", "r162", "r166", "r167", "r168", "r171", "r172", "r218", "r219", "r223", "r227", "r234", "r367", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r40", "r41", "r42", "r81", "r82", "r83", "r85", "r91", "r93", "r117", "r144", "r234", "r241", "r297", "r298", "r299", "r324", "r325", "r358", "r369", "r370", "r371", "r372", "r373", "r374", "r397", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Shareholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r81", "r82", "r83", "r117", "r422" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r64", "r65", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of commitment shares for deferred offering costs subsequently charged to additional paid-in capital" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r15", "r16", "r234", "r235", "r241" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Issuance of Units for cash Fiscal 2021 Equity Financing (in shares)", "verboseLabel": "Sale of units" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r234", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "presentationGuidance": "Number of shares issued", "terseLabel": "Gross proceeds from issuance of common stock for cash (in shares)", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "verboseLabel": "Stock issued during period shares reverse stock splits" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Forfeited", "negatedLabel": "Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r33", "r234", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Issuance of Units for cash Fiscal 2021 Equity Financing" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock for consulting services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r234", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock for cash", "verboseLabel": "Gross proceeds from issuance of common stock for cash" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r19", "r20", "r73", "r142", "r143", "r367", "r409" ], "calculation": { "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders equity:", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r71", "r219", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r241", "r244", "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "verboseLabel": "Reverse stock split, Exchange ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r375", "r411" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent event.", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r375", "r411" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r375", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r375", "r411" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r410", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2021UnderwrittenPublicOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityEquityDistributionAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityLpcPurchaseAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityMay2022RegisteredDirectOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRegistrationRightsAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsJuly2022FinancingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "LIQUIDITY" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL FINANCIAL INFORMATION", "verboseLabel": "SUPPLEMENTARY CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureLoanAndSecurityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "terseLabel": "Unrealized gain (loss) on derivatives" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r122", "r123", "r124", "r125", "r126", "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r258", "r259", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants.", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDerivativeLiabilityAssociatedWithStockOptionsDetails", "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesWeightedAverageAssumptionForValuationsByCharterRevisionDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureDerivativeLiabilitiesForAuthorizedShareDeficienciesDeficiencyTriggeredByIssuanceOfClassBPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityRequiredShareholderApprovalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Weighted average remaining contractual term", "verboseLabel": "Term of warrants" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityFiscal2021EquityFinancingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted average adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r98", "r110" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding - diluted (in shares)", "verboseLabel": "Weighted average shares for diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Calculation of Denominators:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r96", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding - basic (in shares)", "verboseLabel": "Weighted average shares for basic net loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=118255708&loc=SL5909891-110878" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r481": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r482": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r483": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r484": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r485": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r486": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r487": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r488": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r489": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" } }, "version": "2.1" }